Sick Money (Pt 1): Exposing the drug companie...

In the week between Christmas and New Year, we’re revisiting some of our favourite episodes of 2025. This episode was first published in February.A year ago Times columnist James Marriott ditched his smartphone to escape the endless notifications from his apps. How has he managed ...  Show more

From oil spills to climate change, penguins are on the frontline of environmental change. Pablo García Borboroglu has spent more than three decades rescuing colonies, moving shipping lanes, and protecting over 32 million acres of penguin habitat. He joins Adam Vaughan to share wh ...  Show more

On this week's episode of Networth and Chill, I'm joined by author and CEO of Rhoshan Pharmaceuticals, Hitha Palepu to talk drug prices and the pharmaceutical industry. Drug prices are a hot topic these days, and it seems like the cost of life saving medications like insulin and ...  Show more

A year ago, Congress overhauled the way drugs for older Americans get paid for, by giving Medicare the power to bargain with drug makers over prices in the biggest change to health care for more than a decade. This week, the Biden administration began its implementation.

For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.

Rebecca Robbi ...

If you had a rare disease and the only drug that could help you suddenly shot up in price how would you feel? What if your health service or insurer decided it was too expensive and they wouldn’t fund it any more? This is the problem facing some patients in the Netherlands.In ord ...  Show more